Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q1 2021/22 Earnings Presentation
9 slides from Coloplast A/s Class B's earnings presentation, February 2022
Slide 1: Conference call presentation Q1 2021/22
Conference call presentation Q1 2021/22 Making life easier Kirsten, DK STRIVE25: SUSTAINABLE GROWTH LEADERSHIP Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid start in Q1 with 6% organic growth and 32% EBIT margin
Solid start in Q1 with 6% organic growth and 32% EBIT margin1. Financial guidance updated to reflect the Atos Medical acquisition REVENUE GROWTH Q1 2021/22 highlights Reported revenue (mDKK) • Organic growth of 6% and reported growth in DKK of 9% Organic growth • Organic growth by business area: Ost
Slide 4: Q1 growth was driven by the European markets across all business areas
Q1 growth was driven by the European markets across all business areas Q1 2021/22 revenue by business area Q1 2021/22 revenue by geography Business Reported revenue Q1 Organic growth Share of organic Geographic Reported revenue Q1 Organic growth Share of organic area DKKm Q1 growth area DKKm Q1 grow
Slide 5: Q1 reported growth was up 9%, ~3%-points above organic growth
Q1 reported growth was up 9%, ~3%-points above organic growth due to positive impact from currencies, mainly GBP, USD and CNY Revenue development (DKKm) Q1 2021/22 highlights • Reported revenue increased by DKK 431 million, or 9% compared to Q1 2020/21 • Q1 organic growth was 6% or DKK 288 million 1
Slide 6: Reported EBIT margin of 32% in Q1 reflecting increased travel and marketing spend
Reported EBIT margin1 of 32% in Q1 reflecting increased level of travel and marketing spend, partly offset by efficiency gains and FX EBIT margin development before special items (%) Q1 2021/22 highlights • Q1 gross margin was 68%, similar to Q1 last year 0.6 -1.2 • Positive impact from operating le
Slide 7: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments Q1 2021/22 highlights • Free cash flow was DKK 930 million compared to an outflow of DKK 14 million in Q1 2020/21 98 99 98 93 • Adjusted for the Nine Continents Medical acquisition last year, Q1 90 90 2020/21 free cash f
Slide 8: Financial guidance for FY 2021/22 updated with impact from the Atos Medical acquisition
Financial guidance for FY 2021/22 updated with impact from the Atos Medical acquisition GUIDANCE 2021/22 GUIDANCE 2021/22 (DKK)* KEY ASSUMPTIONS • Continued resumption of hospital activity across business areas • Chronic Care: continued improvement in growth in Europe, as a result of normalized grow
Slide 9: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /